Wang, Cheng-YiCheng-YiWangLiao, Kuang-MingKuang-MingLiaoWang, Ya-HuiYa-HuiWangChen, Kuang-HungKuang-HungChenChuang, ShulinShulinChuangCHIA-JUNG LIUCHIN-CHUNG SHUHAO-CHIEN WANG2023-10-202023-10-202023-08-2618760341https://pubmed.ncbi.nlm.nih.gov/37729686/https://scholars.lib.ntu.edu.tw/handle/123456789/636411Type 2 diabetes mellitus (DM) is a risk factor for mycobacterial pulmonary infections (MPI), including tuberculosis (TB) and nontuberculous mycobacterial lung disease (NTM-LD). Dipeptidyl peptidase IV inhibitor (DPP4i), a common DM medication, has an immune-modulation effect that raises concerns about developing MPI. However, there is scarce research on the topic.enDiabetes mellitus; Dipeptidyl peptidase IV inhibitors; Mycobacterial pulmonary infection; Nontuberculous mycobacterial lung disease; Tuberculosis[SDGs]SDG3journal article10.1016/j.jiph.2023.08.018377296862-s2.0-85171479552https://api.elsevier.com/content/abstract/scopus_id/85171479552